Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Targeting novel mechanisms of pain in sickle cell disease.

Tran H, Gupta M, Gupta K.

Blood. 2017 Nov 30;130(22):2377-2385. doi: 10.1182/blood-2017-05-782003. Review.

2.

Targeting novel mechanisms of pain in sickle cell disease.

Tran H, Gupta M, Gupta K.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):546-555. doi: 10.1182/asheducation-2017.1.546. Review.

3.

State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Puri L, Nottage KA, Hankins JS, Anghelescu DL.

Paediatr Drugs. 2018 Feb;20(1):29-42. doi: 10.1007/s40272-017-0263-z. Review.

PMID:
28853040
4.

Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.

De Franceschi L, Mura P, Schweiger V, Vencato E, Quaglia FM, Delmonte L, Evangelista M, Polati E, Olivieri O, Finco G.

Pain Pract. 2016 Jul;16(6):680-7. doi: 10.1111/papr.12313. Epub 2015 May 26.

PMID:
26009799
5.

Morphine for the treatment of pain in sickle cell disease.

Gupta M, Msambichaka L, Ballas SK, Gupta K.

ScientificWorldJournal. 2015;2015:540154. doi: 10.1155/2015/540154. Epub 2015 Jan 12. Review.

6.

Mouse Models of Pain in Sickle Cell Disease.

Sagi V, Song-Naba WL, Benson BA, Joshi SS, Gupta K.

Curr Protoc Neurosci. 2018 Oct;85(1):e54. doi: 10.1002/cpns.54. Epub 2018 Sep 28.

PMID:
30265442
7.

Thinking beyond sickling to better understand pain in sickle cell disease.

Darbari DS, Ballas SK, Clauw DJ.

Eur J Haematol. 2014 Aug;93(2):89-95. doi: 10.1111/ejh.12340. Epub 2014 May 16. Review.

8.

IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies.

Dampier CD, Smith WR, Wager CG, Kim HY, Bell MC, Miller ST, Weiner DL, Minniti CP, Krishnamurti L, Ataga KI, Eckman JR, Hsu LL, McClish D, McKinlay SM, Molokie R, Osunkwo I, Smith-Whitley K, Telen MJ; Sickle Cell Disease Clinical Research Network (SCDCRN).

Clin Trials. 2013 Apr;10(2):319-31. doi: 10.1177/1740774513475850.

9.

Hospitalist management of vaso-occlusive pain crisis in patients with sickle cell disease using a pathway of care.

Allen Liles E, Kirsch J, Gilchrist M, Adem M.

Hosp Pract (1995). 2014 Apr;42(2):70-6. doi: 10.3810/hp.2014.04.1105.

PMID:
24769786
10.

Psychosocial and pharmacological management of pain in pediatric sickle cell disease.

Hildenbrand AK, Nicholls EG, Daly BP, Marsac ML, Tarazi R, Deepti R.

Postgrad Med. 2014 Mar;126(2):123-33. doi: 10.3810/pgm.2014.03.2748. Review.

PMID:
24685976
11.

Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome.

Buchanan ID, Woodward M, Reed GW.

Pediatr Blood Cancer. 2005 Oct 15;45(5):716-24.

PMID:
15926170
12.

Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department.

García-Morin M, López-Sangüos C, Vázquez P, Alvárez T, Marañón R, Huerta J, Cela E.

Hemoglobin. 2016 Nov;40(6):388-391. doi: 10.1080/03630269.2016.1275677.

PMID:
28361592
13.

Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study.

Finkelstein Y, Schechter T, Garcia-Bournissen F, Kirby M, Nurmohamed L, Juurlink DN, Blanchette V, Koren G.

Clin Ther. 2007 Dec;29(12):2738-43. doi: 10.1016/j.clinthera.2007.12.016.

PMID:
18201591
14.

Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.

Neri CM, Pestieau SR, Darbari DS.

Paediatr Anaesth. 2013 Aug;23(8):684-9. doi: 10.1111/pan.12172. Epub 2013 Apr 9. Review.

PMID:
23565738
15.

Pain management in children with sickle cell disease.

Stinson J, Naser B.

Paediatr Drugs. 2003;5(4):229-41. Review.

PMID:
12662119
16.

Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.

Nobrega R, Sheehy KA, Lippold C, Rice AL, Finkel JC, Quezado ZMN.

Pediatr Res. 2018 Feb;83(2):445-454. doi: 10.1038/pr.2017.197. Epub 2017 Sep 13.

PMID:
28902183
17.

Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.

Sheehy KA, Finkel JC, Darbari DS, Guerrera MF, Quezado ZM.

Pain Pract. 2015 Nov;15(8):E90-7. doi: 10.1111/papr.12336. Epub 2015 Jul 23.

18.

Sickle cell disease -- when opioids and physicians fail.

Malach S, Levin T, Saravay S, Martin R, Rao S, Horowitz D.

Gen Hosp Psychiatry. 2002 Nov-Dec;24(6):442-7.

PMID:
12490348
19.

An Expert Review of Pharmacogenomics of Sickle Cell Disease Therapeutics: Not Yet Ready for Global Precision Medicine.

Mnika K, Pule GD, Dandara C, Wonkam A.

OMICS. 2016 Oct;20(10):565-574. Epub 2016 Sep 16. Review.

20.

Acute pain in children and adults with sickle cell disease: management in the absence of evidence-based guidelines.

Field JJ, Knight-Perry JE, Debaun MR.

Curr Opin Hematol. 2009 May;16(3):173-8. doi: 10.1097/MOH.0b013e328329e167. Review.

PMID:
19295432

Supplemental Content

Support Center